Keros Therapeutics, Inc. (KROS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. kros-20260717 0001664710 FALSE 0001664710 2026-07-17 2026-07-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
How this was made
The 30-second read
Why it matters
The key new information is the effective dates of the CFO departure and interim finance leadership, plus the interim officer’s base salary and potential severance/COBRA benefits if terminated without cause or resigning for good reason.
Market read
This is a governance/finance leadership update that can affect investor sentiment, but it does not include financial results, guidance, or any stated accounting-control dispute.
What to watch
Traders may overreact to the CFO headline; the 8-K explicitly says the resignation was not due to accounting/internal control disagreements, reducing the probability of an immediate financial reporting overhang.
Background
Keros filed an SEC Form 8-K (Item 5.02) reporting the resignation of its CFO and the interim appointment of its corporate controller as principal financial and accounting officer.
Ticker impact
Keros Therapeutics disclosed CFO Keith Regnante’s resignation effective Aug. 3, 2026 and named Annita Tanini interim principal financial officer Aug. 4.
Likely limited near-term impact unless investors view the transition as signaling financial-control or funding risk; otherwise modest sentiment effect.
The filing is a primary-source SEC 8-K detailing an executive transition and compensation, but it does not cite accounting disagreements, restatements, or operational guidance changes.
Market effects
No direct sector read-across; this is company-specific governance and finance leadership continuity.
None indicated.
None indicated.
Counterpoint
The interim appointment is internal (controller and VP Finance since 2019), which can be read as continuity rather than disruption.
Key entities
- companyKeros Therapeutics, Inc.
Nasdaq-listed biotech company filing Item 5.02 8-K about CFO departure and interim principal financial officer appointment.
- personKeith Regnante
Resigning Chief Financial Officer, effective Aug. 3, 2026.
- personAnnita Tanini
Corporate Controller and VP Finance appointed interim principal financial officer and principal accounting officer effective Aug. 4, 2026.
